Der Hautarzt

, Volume 57, Issue 8, pp 685–689

Calcineurininhibitoren zur topischen Therapie der Psoriasis

Leitthema

Zusammenfassung

Die spezifische antientzündliche Therapie der Psoriasis bietet vielfältige Möglichkeiten. Eine Option ergibt sich aus der Anwendung von Calcineurininhibitoren. Bisher ist lediglich die systemische Applikation von Ciclosporin A für diese Indikation zugelassen. Grundsätzlich sind aber Ciclosporin A, Tacrolimus und Pimecrolimus als wirksame antiinflammatorische Substanzen zur Therapie der Psoriasis einzustufen. Leider sind die verfügbaren galenischen Systeme für eine topische Anwendung der genannten Wirkstoffe nicht oder nur sehr bedingt geeignet, um eine ausreichende lokale Bioverfügbarkeit der jeweiligen Wirksubstanzen im Zielkompartiment zu gewährleisten. Lediglich unter Nutzung zusätzlicher penetrationsfördernder Maßnahmen bzw. penetrationserleichternder Bedingungen ist eine klinische Wirksamkeit der Präparate nachweisbar. Weiterführende galenische Konzepte lassen einen größeren Stellenwert der Substanzgruppe bei der topischen Therapie der Psoriasis erwarten.

Schlüsselwörter

Calcineurininhibitoren Psoriasis Topische Therapie Tacrolimus Pimecrolimus 

Calcineurin inhibitors for topical therapy in psoriasis

Abstract

There are numerous possibilities for specific antiinflammatory therapy of psoriasis. One option is the use of calcineurin inhibitors. To date, only systemic administration of cyclosporine A is approved for this indication. Nonetheless cyclosporine A, tacrolimus and pimecrolimus can all be classed as effective anti-inflammatory agents for the therapy of psoriasis. Unfortunately, the vehicles currently available do not insure adequate topical delivery of these substances. Clinical efficacy of the preparations can be proven only when additional penetration-promoting measures are used or penetration-facilitating conditions exist. The entire group can be expected to play a greater role in the topical therapy of psoriasis if advances in vehicles and delivery systems are made.

Keywords

Calcineurin inhibitors Psoriasis Topical therapy Tacrolimus Pimecrolimus 

Literatur

  1. 1.
    Amichai B (2004) Psoriasis of the glans penis in a child successfully treated with Elidel (pimecrolimus) cream. J Eur Acad Dermatol Venereol 18: 742–743CrossRefPubMedGoogle Scholar
  2. 2.
    Bigby M (2005) Pimecrolimus and tacrolimus for the treatment of intertriginous and facial psoriasis: are they effective? Arch Dermatol 141: 1152–1153CrossRefPubMedGoogle Scholar
  3. 3.
    Billich A, Vyplel H, Grassberger M et al. (2005) Novel cyclosporin derivates featuring enhanced skin penetration despite increased molecular weight. Bioorg Med Chem 13: 3157–3167CrossRefPubMedGoogle Scholar
  4. 4.
    Bousema MT, Tank B, Heule F et al. (1990) Placebo-controlled study of psoriasis patients treated topically with a 10% cyclosporine gel. J Am Acad Dermatol 22:126–127PubMedGoogle Scholar
  5. 5.
    bu-Elmagd K, van TD, Jegasothy BV, Ackerman CD et al. (1991) FK 506: a new therapeutic agent for severe recalcitrant psoriasis. Transplant Proc 23: 3322–3324PubMedGoogle Scholar
  6. 6.
    Choi HK, Flynn GL, Amidon GL (1995) Percutaneous absorption and dermal delivery of cyclosporin A. J Pharm Sci 84: 581–583PubMedGoogle Scholar
  7. 7.
    Erdogan M, Wright JR Jr, McAlister VC (2002) Liposomal tacrolimus lotion as a novel topical agent for treatment of immune-mediated skin disorders: experimental studies in a murine model. Br J Dermatol 146: 964–967CrossRefPubMedGoogle Scholar
  8. 8.
    Freeman AK, Linowski GJ, Brady C et al. (2003) Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol 48: 564–568CrossRefPubMedGoogle Scholar
  9. 9.
    Gottlieb AB, Griffiths CE, Ho VC et al. (2005) Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. Br J Dermatol 152: 1219–1227CrossRefPubMedGoogle Scholar
  10. 10.
    Grassberger M, Steinhoff M, Schneider D, Luger TA (2004) Pimecrolimus – an anti-inflammatory drug targeting the skin. Exp Dermatol 13: 721–730CrossRefPubMedGoogle Scholar
  11. 11.
    Gribetz C, Ling M, Lebwohl M et al. (2004) Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 51: 731–738CrossRefPubMedGoogle Scholar
  12. 12.
    Griffiths CE, Powles AV, Baker BS et al. (1987) Topical cyclosporin and psoriasis. Lancet 1: 806CrossRefGoogle Scholar
  13. 13.
    Gupta AK, Chow M (2003) Pimecrolimus: a review. J Eur Acad Dermatol Venereol 17: 493–503CrossRefPubMedGoogle Scholar
  14. 14.
    Gupta AK, Fisher GJ, Elder JT et al. (1989) Topical cyclosporine A inhibits the phorbol ester induced hyperplastic inflammatory response but not protein kinase C activation in mouse epidermis. J Invest Dermatol 93: 379–386CrossRefPubMedGoogle Scholar
  15. 15.
    Hermann RC, Taylor RS, Ellis CN et al. (1988) Topical ciclosporin for psoriasis: in vitro skin penetration and clinical study. Skin Pharmacol 1: 246–249PubMedGoogle Scholar
  16. 16.
    Jahn K (2002) Moderne galenische Zubereitungen zur dermalen Anwendung von Ciclosporin A und Mycophenolatmofetil. Shaker, AachenGoogle Scholar
  17. 17.
    Kroft EB, Erceg A, Maimets K et al. (2005) Tacrolimus ointment for the treatment of severe facial plaque psoriasis. J Eur Acad Dermatol Venereol 19: 249–251CrossRefPubMedGoogle Scholar
  18. 18.
    Lebwohl M, Freeman A, Chapman MS et al. (2005) Proven efficacy of tacrolimus for facial and intertriginous psoriasis. Arch Dermatol 141: 1154CrossRefPubMedGoogle Scholar
  19. 19.
    Lebwohl M, Freeman AK, Chapman MS et al. (2004) Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 51: 723–730CrossRefPubMedGoogle Scholar
  20. 20.
    Liu H, Li S, Wang Y et al. (2006) Effect of vehicles and enhancers on the topical delivery of cyclosporin A. Int J Pharm 311: 182–186CrossRefPubMedGoogle Scholar
  21. 21.
    Mansouri P, Farshi S (2006) Pimecrolimus 1 percent cream in the treatment of psoriasis in a child. Dermatol Online J 12: 7Google Scholar
  22. 22.
    Marsland AM, Griffiths CE (2002) The macrolide immunosuppressants in dermatology: mechanisms of action. Eur J Dermatol 12: 618–622PubMedGoogle Scholar
  23. 23.
    Mrowietz U, Graeber M, Brautigam M et al. (1998) The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 139: 992–996CrossRefPubMedGoogle Scholar
  24. 24.
    Mrowietz U, Wustlich S, Hoexter G et al. (2003) An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. Acta Derm Venereol 83: 351–353CrossRefPubMedGoogle Scholar
  25. 25.
    Ortonne JP, van de Kerkhof PC, Prinz JC et al. (2006) 0.3% Tacrolimus gel and 0.5% Tacrolimus cream show efficacy in mild to moderate plaque psoriasis: results of a randomized, open-label, observer-blinded study. Acta Derm Venereol 86: 29–33PubMedGoogle Scholar
  26. 26.
    Pharmazeutisches Laboratorium des „Neuen Rezeptur-Formularium“ (2004) Standardisierte Rezepturen. Govi, EschbornGoogle Scholar
  27. 27.
    Rallis E, Nasiopoulou A, Kouskoukis C et al. (2005) Successful treatment of genital and facial psoriasis with tacrolimus ointment 0.1%. Drugs Exp Clin Res 31: 141–145PubMedGoogle Scholar
  28. 28.
    Rappersberger K, Komar M, Ebelin ME et al. (2002) Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol 119: 876–887CrossRefPubMedGoogle Scholar
  29. 29.
    Scheinfeld N (2004) The use of topical tacrolimus and pimecrolimus to treat psoriasis: a review. Dermatol Online J 10: 3Google Scholar
  30. 30.
    Schulze HJ, Mahrle G, Steigleder GK (1990) Topical cyclosporin A in psoriasis. Br J Dermatol 122: 113–114PubMedGoogle Scholar
  31. 31.
    Steele JA, Choi C, Kwong PC (2005) Topical tacrolimus in the treatment of inverse psoriasis in children. J Am Acad Dermatol 53: 713–716CrossRefPubMedGoogle Scholar
  32. 32.
    The European FK 506 Multicentre Psoriasis Study Group (1996) Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch Dermatol 132: 419–423CrossRefPubMedGoogle Scholar
  33. 33.
    Tosti A, Guerra L, Bardazzi F, Lanzarini M (1990) Topical ciclosporin in nail psoriasis. Dermatologica 180: 110Google Scholar
  34. 34.
    Wolff K (2004) Current concepts and review of pimecrolimus in the treatment of psoriasis. Dermatol Clin 22: 461–465PubMedGoogle Scholar
  35. 35.
    Yamamoto T, Nishioka K (2000) Topical tacrolimus is effective for facial lesions of psoriasis. Acta Derm Venereol 80: 451PubMedGoogle Scholar
  36. 36.
    Yocum DE (1996) Cyclosporine, FK-506, rapamycin, and other immunomodulators. Rheum Dis Clin North Am 22: 133–154CrossRefPubMedGoogle Scholar
  37. 37.
    Zonneveld IM, Rubins A, Jablonska S et al. (1998) Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol 134: 1101–1102CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2006

Authors and Affiliations

  1. 1.Universitätsklinik und Poliklinik für Dermatologie und Venerologie, Institut für angewandte DermatopharmazieMartin-Luther-Universität Halle-WittenbergHalle

Personalised recommendations